Donald Trump has declared a new wave of trade actions, applying 100 percent tariffs to imported patented medications, a step that would promote its production in the United States. It is decided a year after his previous policy of reciprocal tariff that was reversed by the US Supreme Court.
The new tariffs are specifically aimed at patented medications, and the administration mentions the issue of national security and susceptibility to the global supply chains as the primary motives of the action. According to the officials, the move is a result of an internal review that has revealed the dangers of depending on the production of pharmaceuticals abroad, particularly those that are key to the body.
It is notable that the current tariff regime has been applied to generic medicines and has been omitted. Nevertheless, the US officials have suggested that this exemption might not be a long-term one, as they have threatened to take further steps in case the global producers fail to transfer their production to the American territory.
The exemption of generics is especially important to India. The Indian pharmaceutical firms dominate the global generics market and also are the biggest exporters to the US. The extension of generic drugs is a temporary reprieve and contributes to the maintenance of the supply of cheap medicine, which constitutes a significant portion of the Indian pharmaceutical export to the US.
Experts in the industry say that the move may redefine pharmaceutical supply chains around the globe in the long run, which would force multinational firms to rethink their production destinations. The short term effect in India is not substantial but in the long term, it will depend on the policy development and whether the generics exemption will be maintained.